TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04749017

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental product consumption
Description: Consumption of the experimental product 2 capsules daily, morning and evening (450 mg each capsule) for 60 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control product consumption
Description: Consumption of control product of identical appearance 2 capsules daily for 60 days, morning and evening
Study: NCT06233019

Intervention type: OTHER
Group type: OTHER
Intervention: Glycolic Acid Plus Salicylic Acid in Treatment of Plane Wart
Description: Prior to the procedure, patients will be instructed to avoid sun exposure during the treatment and to use broad spectrum sunscreen The treatment was started once daily over the entire face and maintained for two months. A fine layer of Glycolic Acid Plus Salicylic Acid face gel was applied on the whole surface where the warts were present, avoiding the eyelids and lips. In children 7 to 10 years of age, face gel was applied by their parents. Clinical controls were performed at Weeks 2, 4, 6, and 8.
Study: NCT04481373

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE
Description: The ACT components (3-3.5 hours) will focus on clarifying patient values and goals and identifying obstacles that may be getting in the way of living a rich life. Short-and long-term effects of avoidance will be discussed (e.g., avoidance reduces immediate contact with distressing experiences and provides short-term relief but leads to greater dysfunction in long run). Patients will be taught acceptance, mindfulness, and perspective taking to help patient cope with difficult emotions and thoughts that may interfere with living a values-driven life. Individuals will also be encouraged to examine the costs of stigmatization on their life (e.g. avoidance of medical care, sense of isolation).~Education will include medical information about HIV, services available at the clinic, and health needs related to comorbidities. This content to be delivered in 30 minutes.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Patients get usual care at the hospital. Service linkage workers (SLWs) meet with all hospitalized PWH and cover educational aspects of the care.
Study: NCT06554327

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multiplex PCR
Description: In the intervention group (Multiplex PCR performed and results communicated to the clinician), bronchoalveolar lavage will be examined directly after Gram staining by the laboratory, followed by quantitative culture. A multiplex PCR will be performed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiplex PCR
Description: In the intervention group (Multiplex PCR performed and results communicated to the clinician), bronchoalveolar lavage will be examined directly after Gram staining by the laboratory, followed by quantitative culture. A multiplex PCR will be performed.
Study: NCT05311137

Intervention type: PROCEDURE
Intervention: Radiofrequency ablation
Description: Combined use of radiofrequency ablation, cryoablation, left bundle branch pacing, and left atrial appendage closure according to the actual situation of the patient.

Intervention type: PROCEDURE
Intervention: Radiofrequency ablation
Description: Combined use of radiofrequency ablation, cryoablation, left bundle branch pacing, and left atrial appendage closure according to the actual situation of the patient.
Study: NCT06441539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bingo® Paclitaxel coated balloon
Description: Treat the main vessel and side branch of bifurcation lesion with drug-eluting balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Xience® Alpine Everolimus Eluting Coronary Stent System
Description: Treat the main vessel of bifurcation lesion with drug-eluting stent, and treat the side branch with uncoated balloon or drug-eluting stent
Study: NCT04825041

Intervention type: DIAGNOSTIC_TEST
Intervention: Patency test
Description: Successive flow test, bubble flow test and peristalsis test
Study: NCT05942963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: 10-25 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: 10-25 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg
Description: 15-45 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15mg
Description: 15-45 mg/day
Study: NCT06336551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy for insomnia (ACT-I)
Description: During ACT-I patients are encouraged to let go of the struggle to control sleep and to focus on meaningful daytime activities. Treatment goals are addressed through ACT processes of creative hopelessness and self-as-context (session 1), acceptance (session 2), defusion (session 3), followed by values, committed action, and present moment awareness (sessions 4 and 5).
Study: NCT05565300

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycling exercise
Description: 30 minutes of cycling (90 rpm).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling exercise
Description: 30 minutes of cycling (90 rpm).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive tasks
Description: 30 minutes of cognitive tasks based on the different domains of the Mini Mental Scale.
Study: NCT06349733

Intervention type: DRUG
Group type: OTHER
Intervention: Botulinum toxin type A
Description: Eligible patients were randomly assigned to the experimental group and the control group. Patients in the experimental group will be randomized to receive injections of 1 U,2.5 U, and 5 U botulinum toxin type A,Patients in the control group received an injection of 0.9% Nacl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Eligible patients were randomly assigned to the experimental group and the control group. Patients in the experimental group will be randomized to receive injections of 1 U,2.5 U, and 5 U botulinum toxin type A,Patients in the control group received an injection of 0.9% Nacl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Eligible patients were randomly assigned to the experimental group and the control group. Patients in the experimental group will be randomized to receive injections of 1 U,2.5 U, and 5 U botulinum toxin type A,Patients in the control group received an injection of 0.9% Nacl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Eligible patients were randomly assigned to the experimental group and the control group. Patients in the experimental group will be randomized to receive injections of 1 U,2.5 U, and 5 U botulinum toxin type A,Patients in the control group received an injection of 0.9% Nacl
Study: NCT05696171

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear implant manual insertion
Description: Manual insertion of the cochlear implant into the round window during the surgery
Study: NCT05717270

Intervention type: PROCEDURE
Intervention: Two-layered suture repair
Description: The ruptured Achilles tendon will be sutured in two-layer.
Study: NCT06504147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radspherin
Description: Radspherin® suspension consists of bio-degradable calcium carbonate micro particles with the α-emitting radionuclide 224Ra in suspension. 224Ra has a physical half-life of 3.6 days.
Study: NCT06557330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered as 10 minute IV infusion at 90 mg/m2 (drug dose calculation is based on treatment day weight) on days 1 and 2 for 4-6 cycles (number of cycles determined per treatment design). Subjects will be dosed every 28 days. Ondansetron 16 mg IV is given as premedication per institutional guidelines. Dose modifications will be determined based on renal and hepatic function. Subjects should be carefully monitored for infusion reactions during Bendamustine administration. If an acute infusion reaction is noted, subjects should be managed according to institutional guidelines. Doses of Bendamustine may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment based on physician discretion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered as an IV infusion at 375 mg/m2 (longer for the first dose) (drug dose calculation is based of treatment day weight) on day 1 for 4-6 cycles (number of cycles determined per treatment design). Infusion rate will be determined as per institutional standards. Subjects will be dosed every 28 days. Diphenhydramine 50 mg IV and acetaminophen 650 mg are required to be given to the subjects within 30 minutes prior to Rituximab dose. There are no dose modifications recommended with Rituximab. If an acute infusion reaction is noted, subjects should be managed according to institutional guidelines. Doses of Rituximab may be interrupted, delayed, or discontinued depending on how well the subject tolerates the treatment.
Study: NCT06239961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Connection
Description: 6 weekly Behavioral Activation Intervention calls with a 1 hour duration for each call.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional Coaching
Description: 4 weekly nutritional coaching calls with a Registered Dietician with a 1 hour duration for each call.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Coaching
Description: 4 weekly physical activity coaching sessions with a 1 hour duration for each call.
Study: NCT04265950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given IM
Study: NCT04873362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg every three weeks (Q3W) for 14 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg Q3W for 14 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Emtansine
Description: Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg Q3W for 14 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matched to atezolizumab will be administered at a dose of 1200 mg Q3W for 14 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab will be used to complete 14 cycles of study treatment if trastuzumab emtansine is discontinued for toxicity not considered to be related to the trastuzumab component of the drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab will be used to complete 14 cycles of study treatment if trastuzumab emtansine is discontinued for toxicity not considered to be related to the trastuzumab component of the drug.
Study: NCT05591092

Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo a SPECT/CT scan

Intervention type: RADIATION
Intervention: Iodine I-123
Description: Given PO

Intervention type: PROCEDURE
Intervention: Planar Imaging
Description: Undergo planar imaging

Intervention type: PROCEDURE
Intervention: Single Photon Emission Computed Tomography
Description: Undergo a SPECT/CT scan
Study: NCT06118892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MISHA Knee System
Description: The MISHA Knee System is an extra-capsular knee implant intended to reduce loads on the medial knee. The implant consists of an absorber located between bases fixed with locking screws to the medial cortices of the distal femur and proximal tibia. The implant shares the load with the medial knee joint and articulating ball-and-sockets allow the device to accommodate the natural motions of the knee.
Study: NCT05674851

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: collection of MRI scans for mathematical model development
Study: NCT05160636

Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: Receipt of Pfizer BioNTech COVID-19 vaccine
Study: NCT04955821

Intervention type: DIAGNOSTIC_TEST
Intervention: mNGS diagnose of VAP
Description: This study is an observational study to evaluate the accuracy of pathogens in children with VAP tested by mNGS with no intervention. All patients from the cohort accept mNGS test and bacterial culture or virus PCR detection. A double sputum specimens are used for test.The reference standard is bacterial culture or virus PCR detection.
Study: NCT05942963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1000mg-2850mg/ day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1000mg-2850mg/ day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 1000mg-2850mg/ day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1000mg-2850mg/ day
Study: NCT05881577

Intervention type: OTHER
Intervention: Observational
Description: Impact of AR on educational outcomes
Study: NCT04635267

Intervention type: OTHER
Intervention: Prone position in patients with ARDS
Description: Transpulmonary thermodilution, arterial blood gas and recruitment/inflation calculation will be made every 8 hours: at baseline (just before prone position), after eight hours of prone position, after 16 hours of prone position (end of prone position), after 24 hours ( 8 hours after the end of prone position).
Study: NCT05983107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus combined with endocrine therapy（tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide combined with endocrine therapy（tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc.goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator）

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc, selected at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endocrine therapy
Description: Tamoxifen, letrozole, anastrozole, exemestane, fulvestrant, etc, selected at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovarian function suppression(OFS)
Description: Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovarian function suppression(OFS)
Description: Goserelin, leuprolide, premenopausal patients only, selected at the discretion of the investigator.
Study: NCT05744193

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exempt Infant Formula
Description: Liquid human milk fortifier to be added to human milk daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exempt Infant Formula
Description: Liquid human milk fortifier to be added to human milk daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exempt Infant Formula
Description: Liquid human milk fortifier to be added to human milk daily
Study: NCT05696171

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cochlear implant robotized insertion
Description: Robotic insertion of the cochlear implant into the round window during the surgery
Study: NCT04817072

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample (20mL) for pro-inflammatory cytokines assay
Study: NCT06259279

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity high impact exercise intervention
Description: Patients in the intervention group will receive a 32-week exercise-based intervention that includes:~- Supervised and group-based exercise training in the hospital, twice a week. Each session lasts approximately 30 minutes.
Study: NCT05129254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractionated Thulium laser
Description: For this study, the investigators will use non-ablative fractional Thulium laser (1927 nm), provided by LaseMD, (Lutronic, Inc, USA). The non-ablative fractionated treatments with minimal downtime provide synergistic benefit of minimizing tissue damage while improving treatment tolerance and efficiency. The laser works by creating micro-channels in the dermis of the pilosebaceous unit, while leaving bridges of untouched tissue for improved permeability, faster healing, and enhanced delivery of topical treatments. The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by LaseMD. More than one affected area of the scalp may be treated per session. Each laser treatment will take approximately 10 to 15 minutes per subject. Pretreatment preparation will consist of cleaning the affected area of the scalp with antiseptic, either 70% ethanol or 3% hydrogen peroxide.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma Injection
Description: Platelet rich plasma (PRP) will be collected from participant in accordance with FDA section 21CFR640.34 regulation on collection and preparation of PRP. The collected blood will be processed according to manufacturer protocol to obtain PRP, which will be injected with a syringe and needle subcutaneously into the participant's scalp.
Study: NCT06441786

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A metacognitive group therapy of depression and anxiety in youth with autism
Description: The treatment model is based on Adrian Wells' transdiagnostic A-M-C model and treatment structure described in Wells (2009) Metacognitive therapy for anxiety and depression. The group treatment is delivered in 10 weekly sessions.
Study: NCT05727202

Intervention type: DIAGNOSTIC_TEST
Intervention: The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel
Description: A multiplex real-time PCR IVD test for the qualitative detection and identification of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus (RSV).

Intervention type: DIAGNOSTIC_TEST
Intervention: The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel
Description: A multiplex real-time PCR IVD test for the qualitative detection and identification of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus (RSV).

Intervention type: DIAGNOSTIC_TEST
Intervention: The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel
Description: A multiplex real-time PCR IVD test for the qualitative detection and identification of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus (RSV).

Intervention type: DIAGNOSTIC_TEST
Intervention: The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel
Description: A multiplex real-time PCR IVD test for the qualitative detection and identification of SARS-CoV-2, influenza A virus, influenza B virus, and respiratory syncytial virus (RSV).
Study: NCT05129254

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma Topical Application
Description: Platelet rich plasma (PRP) will be collected from participant in accordance with FDA section 21CFR640.34 regulation on collection and preparation of PRP. The collected blood will be processed according to manufacturer protocol to obtain PRP, which will be applied topically with a syringe to one or more affected areas on the participant's scalp that were previously treated with thulium laser.
Study: NCT05794724

Intervention type: PROCEDURE
Intervention: Surgical resection
Description: Surgical resection of lung adenocarcinoma. Wedge resection, segmentectomy or lobectomy will be performed according to each patients' condition.
Study: NCT05540652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Queer Resilience (MBQR)
Description: Mindfulness-based Queer Resilience (MBQR) is an internet delivered group-based, LGBTQ affirmative mindfulness program designed to address minority stress and promote mental and sexual health among young adult gay, bisexual, and queer men. The intervention group will meet once a week for up to 2.5 hours for nine weeks. Participants will receive free training in meditation, mindful movements, and in directing mindfulness-based skills towards enhancing things like stress recovery, sleep, resilience, cognitive performance and social relationships. MBQR was adapted from the Mindfulness-Based Stress Reduction program. Customization of the curriculum was developed by queer researchers and teachers, with input from the LGBTQ community.
Study: NCT04104555

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Birthday card
Description: Birthday card sent to participants in the post

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prefabricated orthoses
Description: Prefabricated insole

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Signposting to multimedia
Description: Signposting to multimedia information in the patient information sheet which is sent to participants in the post as part of the OSTRICH recruitment pack.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual supportive care - exercises and footwear advice (the comparator)
Description: Active comparator
Study: NCT06336213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ampicillin-sulbactam
Description: If a patient meets dual criteria (presepsin \> 519,5 pg/ml at the end of surgery and the absence of presepsin increase after 6 hours after the end of surgery) then switching to ampicillin/sulbactam 3 g every 6 hours at least 72 h after the surgery is done.
Study: NCT04817189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEPA (300mg netupitant/0.5mg palonosetron)
Description: Oral netupitant/palonosetron (300 mg/0.50 mg) fixed-dose combination on Day 1 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron, 2 mg (oral) or 1 mg (IV) OR Palonosetron, 0.5 mg (oral), 0.25mg (IV) OR Ondansetron, 16 mg (oral) or 8 mg (IV) OR Dolasetron 100 mg (oral) OR Tropisetron 5 mg (oral or IV)
Description: Standard of care will be administered on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, 8 mg (oral) or equivalent IV dose
Description: Dexamethasone (8 mg) will be administered on Day 1 of each cycle.